Digest Network Come funziona
Network
/
Società
Ci
Non verificato

City Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaSaluteSanità

7 comunicati stampa

Guarda tutti i comunicati
08/06/2026
Scienza
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
City Therapeutics Announces $99.5 Million Series B Financing to Advance Next-Generation RNAi Therapeutics
Fonte
City Therapeutics, Inc.
Emittente
Business Wire
1.00
0
06/05/2026
Industria
Oncologia
Salute
Sanità
Farmaceutica
Biotecnologia
City Therapeutics Presents Preclinical Data on Next-Generation Investigational RNAi Therapy CITY-RBP4 for Treatment of Stargardt Disease at ARVO 2026 Annual Meeting
Fonte
City Therapeutics, Inc.
Emittente
Business Wire
1.00
0
10/11/2025
Industria
Scienza
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Sanità
City Therapeutics Announces Submission of Clinical Trial Application for CITY-FXI, an Investigational RNAi Therapeutic for the Treatment of Thromboembolic Diseases
Fonte
City Therapeutics, Inc.
Emittente
Business Wire
1.00
0
17/04/2025
Mercato del lavoro
Biotecnologia
Farmaceutica
Salute
City Therapeutics Expands Executive Team and Board of Directors
Fonte
City Therapeutics, Inc.
Emittente
Business Wire
1.00
0
10/01/2025
Mercato del lavoro
Industria
Salute
Biotecnologia
Sanità
Farmaceutica
Ottica
City Therapeutics Announces Strategic Collaboration with Bausch + Lomb to Develop a Novel RNAi-Based Treatment for Geographic Atrophy
Fonte
City Therapeutics, Inc.
Emittente
Business Wire
1.00
0
07/01/2025
City Therapeutics Appoints Andy Orth as Chief Executive Officer
Fonte
City Therapeutics, Inc.
Emittente
Business Wire
1.00
0
08/10/2024
Industria
Scienza
Biotecnologia
Farmaceutica
Salute
Igiene alimentare
Medicina - Varie
City Therapeutics Launches with $135 Million Series A Financing to Lead the Future of RNAi-based Medicine
Fonte
City Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0